Accuray announced it will not provide formal revenue or adjusted EBITDA guidance for fiscal 2027, instead expecting approximately $15 million of incremental annualized cost and margin improvement. The company reported fourth quarter net revenue of $100.9 million and full fiscal year 2026 revenue of $402 million, with a full-year operating loss of $26.4 million and adjusted EBITDA of $10.6 million. Management highlighted a comprehensive transaction with TCW Asset Management Company that includes conversion of $40 million of existing debt into preferred equity and a $15 million cash investment. Accuray also cited nonbinding letters of intent with Samsung HME America and RaySearch Laboratories, and a 10-year strategic collaboration with the University of Wisconsin School of Medicine and Public Health. The company plans to implement a reverse stock split at a ratio still to be determined and subject to stockholder approval.
Accuray IncorporatedWithholds FY27 guidance but expects cost improvements and announces financing transactions, mixed impact.
